2020–2025 Update on the Comprehensive Care of Patients with Chronic Simple Glaucoma
Keywords:
GLAUCOMA CRÓNICO SIMPLE; ATENCIÓN INTEGRAL; NEUROPROTECCIÓN; TELE OFTALMOLOGÍA; ADHERENCIA TERAPÉUTICA.; CHRONIC SIMPLE GLAUCOMA; COMPREHENSIVE CARE; NEUROPROTECTION; TELEOPHTHALMOLOGY; THERAPEUTIC ADHERENCE.; GLAUCOMA DE ÂNGULO ABERTO; ASSISTÊNCIA INTEGRAL; NEUROPROTEÇÃO; TELEOFTALMOLOGIA; COOPERAÇÃO E ADESÃO AO TRATAMENTO.Abstract
Introduction: chronic simple glaucoma (CSG), also known as primary open-angle glaucoma (POAG), is the leading cause of irreversible blindness worldwide, currently affecting over 80 million people. By 2040, this number is projected to rise to 111 million.
Objective: to conduct a literature review on the comprehensive management of chronic simple glaucoma.
Methods: twenty-eight key studies were analyzed, selected through systematic searches in PubMed, Scopus, and SciELO.
Results: findings highlight recent advances in molecular biomarkers, minimally invasive glaucoma surgery (MIGS), and tele-ophthalmology models. However, challenges persist regarding treatment adherence and equitable access to care. Integrated management requires early detection, multidisciplinary care, patient education, and technological innovation. Despite global initiatives such as the WHO’s Vision 2020/2030, socioeconomic, geographic, and health literacy barriers continue to hinder progress, necessitating adaptive care models.
Conclusions: the integration of artificial intelligence, tiered care pathways, and personalized educational programs constitutes a cornerstone for optimizing visual outcomes and quality of life in patients with CSG.
Downloads
References
1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology [Internet]. 2014 Nov [Citado 20/09/2025]; 121(11): 2081-90. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24974815/
2. Liu H, Chen C, Chen Z, Li Q, Li Q, Liu W. Factors associated with delayed first ophthalmological consultation for primary glaucoma: a qualitative interview study. Front. Med [Internet]. 2014 Nov [Citado 20/09/2025]; 10: 1161980. Disponible en: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1161980/full
3. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA Med [Internet]. 2014 May 14 [Citado 20/09/2025]; 311(18): 1901-11. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC4523637/
4. Jayaram H, et al. Glaucoma: now and beyond. The Lancet [Internet]. 2014 May 14 [Citado 20/09/2025]; 402 (10414): 1788 – 1801. Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01289-8/abstract
5. Bailey JN, Loomis SJ, Kang JH, Allingham RR, Gharahkhani P, Khor CC, et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet [Internet]. 2016 Feb [Citado 20/09/2025]; 48(2): 189-94. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26752265/
6. Stein JD, Khawaja AP, Weizer JS. Glaucoma in Adults-Screening, Diagnosis, and Management: A Review. JAMA [Internet]. 2021 Jan 12 [Citado 20/09/2025]; 325(2): 164-174. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33433580/
7. Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern®. Ophthalmology [Internet]. 2021 Jan [Citado 20/09/2025]. 128(1): P71-P150. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34933745/
8. Bott D, Subramanian A, Edgar D, Lawrenson JG, Campbell P. Barriers and enablers to medication adherence in glaucoma: A systematic review of modifiable factors using the Theoretical Domains Framework. Ophthalmic Physiol Opt [Internet]. 2024 Jan [Citado 20/09/2025]; 44(1): 96-114. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37985237/
9. Thompson C. Clinical experience as evidence in evidence-based practice. J Adv Nurs[Internet]. 2003 [Citado 20/09/2025]; 43(3): 230-237 Disponible en: https://doi.org/10.1046/j.1365-2648.2003.02705.x
10. Pinazo-Duran MD. Editorial: New perspectives in glaucoma pathophysiology, diagnosis, and treatment. Front Med (Lausanne) [Internet]. 2023 May 3 [Citado 20/09/2025]; 10: 1200427. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10189111/
11. Drewry M, Helwa I, Allingham RR, Hauser MA, Liu Y. miRNA Profile in Three Different Normal Human Ocular Tissues by miRNA-Seq. Investigative ophthalmology & visual science[Internet]. 2016[Citado 20/09/2025]; 57(8): 3731–3739. Disponible en: https://doi.org/10.1167/iovs.16-19155
12. Moghimi S, Speilburg A, Durbin MK, Hou H, El-Nimri NW, Lee CK, Guzman A, Arias JD, et al. The Development and Validation of a Glaucoma Health Score for Glaucoma Screening Based on Clinical Parameters and Optical Coherence Tomography Metrics. Journal of Clinical Medicine[Internet]. 2024 [Citado 20/09/2025]; 13(22):6728. Disponible en: https://doi.org/10.3390/jcm13226728
13. Agbato D, Rickford K, Laroche D. Central Corneal Thickness and Glaucoma Risk: The Importance of Corneal Pachymetry in Screening Adults Over 50 and Glaucoma Suspects. Clin Ophthalmol [Internet]. 2025 Feb 15 [Citado 20/09/2025]; 19: 563-570. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC11837748/
14. Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up. Ophthalmology [Internet]. 2015 Oct [Citado 20/09/2025]; 122(10):2010-21. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26319441/
15. Careaga Cacace DM, Arrúa Caballero MF, González Sanabria L, Vera Duarte GR. Comparación de Latanoprostene bunod 0,024 % y Latanoprost 0,005 % en glaucoma de ángulo abierto e hipertensión ocular. Medicina clínica y social [20/09/2025]; 7(1): 26-33. Disponible en: https://www.medicinaclinicaysocial.org/index.php/MCS/article/view/269
16. Gazzard G, Konstantakopoulou E, Garway-Heath D, Adeleke M, Vickerstaff V, Ambler G, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension. Ophthalmology [Internet]. 2023 Feb [Citado 20/09/2025]; 130(2): 139-151. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36122660/
17. Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol [Internet]. 2012 Mar [Citado 20/09/2025]; 23(2): 96-104. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22249233/
18. Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol [Internet]. 2012 Jan [Citado 20/09/2025]; 153(1):1-9.e2. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21872203/
19. Johnson TV, Di Polo A, Sahel JA, Schuman JS. Neuroprotection, Neuroenhancement, and Neuroregeneration of the Retina and Optic Nerve. Ophthalmol Sci [Internet]. 2022 Sep 5 [Citado 20/09/2025]; 2(3): 100216. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9559091/
20. Gan K, Liu Y, Stagg B, Rathi S, Pasquale LR, Damji K. Telemedicine for Glaucoma: Guidelines and Recommendations. Telemed J E Health [Internet]. 2020 Apr [Citado 20/09/2025]; 26(4): 551-555. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC7187965/
21. Davuluru SS, Jess AT, Kim JSB, Yoo K, Nguyen V, Xu BY. Identifying, Understanding, and Addressing Disparities in Glaucoma Care in the United States. Transl Vis Sci Technol [Internet]. 2023 Oct 3 [Citado 20/09/2025]; 12(10): 18. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10617640/
22. O'Day R, Smith C, Muir J, Turner A. Optometric use of a teleophthalmology service in rural Western Australia: comparison of two prospective audits. Clin Exp Optom[Internet]. 2016[Citado 20/09/2025]; 99:163–7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26956453/
23. Gupta D, Chen PP. Glaucoma. Am Fam Physician[Internet]. 2016 Apr 15 Citado 20/09/2025]; 93(8):668-74. Disponible en: https://pubmed-ncbi-nlm-nih-gov.translate.goog/27175839/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nayaris Gómez Martínez, Nairovys Gómez Martínez, Henry Pérez González
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
